Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neoplasms|Prostate Cancer|Lung Cancer|Breast Cancer|Colon Cancer
Interventions: BIOLOGICAL: ETBX-051; adenoviral brachyury vaccine|BIOLOGICAL: ETBX-061; adenoviral Mucin-1 (MUC1) vaccine|BIOLOGICAL: ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine
Sponsor: National Cancer Institute (NCI)